A Benefit-Risk Assessment of Agomelatine in the Treatment of Major Depression

P02-378 - Agomelatine in the treatment of obsesive-compulsive-disorder: Potential for clinical effectiveness: An 4-week, multicenter, randomized, placebo-controlled trial

(2011) P. Marqués Cabezas et al.   EUROPEAN PSYCHIATRY

Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study

(2010) Anthony Hale et al.   INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY

Efficacy of the Novel Antidepressant Agomelatine on the Circadian Rest-Activity Cycle and Depressive and Anxiety Symptoms in Patients With Major Depressive Disorder

(2010) Siegfried Kasper et al.   JOURNAL OF CLINICAL PSYCHIATRY

Agomelatine in the Treatment of Major Depressive Disorder

(2010) Stephen M. Stahl et al.   JOURNAL OF CLINICAL PSYCHIATRY

Efficacy and Safety of Agomelatine in the Treatment of Major Depressive Disorder

(2010) John Zajecka et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Therapeutic Armamentarium for Treating Depression

(2010) Robert H. Howland   POSTGRADUATE MEDICINE

Does agomelatine block 5-HT2C receptors in humans?

(2010) Ann L. Sharpley et al.   PSYCHOPHARMACOLOGY

Can Phase III Trial Results of Antidepressant Medications Be Generalized to Clinical Practice? A STAR*D Report

(2009) Stephen R. Wisniewski et al.   AMERICAN JOURNAL OF PSYCHIATRY

Antagonism of serotonergic 5-HT2A/2Creceptors: mutual improvement of sleep, cognition and mood?

(2009) H.-P. Landolt et al.   EUROPEAN JOURNAL OF NEUROSCIENCE

Agomelatine Prevents Relapse in Patients With Major Depressive Disorder Without Evidence of a Discontinuation Syndrome

(2009) Guy M. Goodwin et al.   JOURNAL OF CLINICAL PSYCHIATRY

Evaluating the Safety of Medications During Pregnancy and Lactation

(2009)   JOURNAL OF PSYCHOSOCIAL NURSING AND MENTAL HEALTH SERVICES

Prescribing Psychotropic Medications During Pregnancy and Lactation

(2009) Robert H. Howland   JOURNAL OF PSYCHOSOCIAL NURSING AND MENTAL HEALTH SERVICES

Influence of the novel antidepressant and melatonin agonist/serotonin2C receptor antagonist, agomelatine, on the rat sleep–wake cycle architecture

(2009) Amandine Descamps et al.   PSYCHOPHARMACOLOGY

Agomelatine Treatment of Major Depressive Disorder

(2008) Christian R Dolder et al.   ANNALS OF PHARMACOTHERAPY

Efficacy of Agomelatine in Generalized Anxiety Disorder

(2008) Dan J. Stein et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

A Double-Blind Comparison of Sexual Functioning, Antidepressant Efficacy, and Tolerability Between Agomelatine and Venlafaxine XR

(2008) Sidney H. Kennedy et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Better sexual acceptability of agomelatine (25 and 50 mg) compared with paroxetine (20 mg) in healthy male volunteers. An 8-week, placebo-controlled study using the PRSEXDQ-SALSEX scale

(2008) AL Montejo et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Clinical Features and Functioning of Patients with Minor Depression

(2008) Robert H. Howland et al.   PSYCHOTHERAPY AND PSYCHOSOMATICS